Related Experiment Video
Updated: Sep 26, 2026
Reduced Complications after Arterial Reconnection in a Rat Model of Orthotopic Liver Transplantation
Published on: November 7, 2020
Sirolimus in liver transplantation
1Division of Gastroenterology/Hepatology, University of Colorado Health Sciences Center, Boulder, Colorado 80262, USA. James.Trotter@uchsc.edu
Abstract:
Since its introduction in renal transplantation in 1999, sirolimus is being used by an increasing number of liver transplant centers. Compared to the calcineurin inhibitors, sirolimus acts through a separate signal transduction pathway and has a myriad of important biologic effects including: inhibition of lymphocyte proliferation, inhibition of fibrosis and fibroblast proliferation, and antineoplastic effects. The clinical side-effect profile of this drug is also different than calcineurin inhibitors. Most important, sirolimus does not cause glucose intolerance, hypertension, or renal insufficiency. As a result, this drug offers significant potential advantages over conventional immunosuppressive agents. However, sirolimus may cause hyperlipidemia and has also been associated with hepatic artery thrombosis in liver transplant recipients. This review will summarize the published data on sirolimus in liver transplantation, focusing on the potential advantages and disadvantage of the use of this drug in liver transplant recipients. Finally, the potential benefits of antifibrosis and antineoplastic effects of sirolimus in liver transplant recipients will be discussed.
Insights
Sirolimus offers potential advantages in liver transplantation due to its unique immunosuppressive, antifibrotic, and antineoplastic effects. However, careful monitoring is needed for side effects like hyperlipidemia and hepatic artery thrombosis.
Area of Science:
- Immunology
- Transplantation Medicine
- Pharmacology
Background:
- Sirolimus, an mTOR inhibitor, is increasingly adopted in liver transplantation since 1999.
- It exhibits distinct immunosuppressive, antifibrotic, and antineoplastic properties compared to calcineurin inhibitors.
- Its unique side-effect profile presents potential advantages over traditional immunosuppressants.
Purpose of the Study:
- To review the published data on sirolimus use in liver transplantation.
- To focus on the advantages and disadvantages of sirolimus in this patient population.
- To discuss the antifibrotic and antineoplastic benefits of sirolimus in liver transplant recipients.
Main Methods:
- Literature review of published data on sirolimus in liver transplantation.
- Analysis of clinical side-effect profiles.
- Evaluation of biologic effects including immunosuppression, antifibrosis, and antineoplasia.
Main Results:
- Sirolimus inhibits lymphocyte proliferation, fibrosis, and fibroblast proliferation.
- Unlike calcineurin inhibitors, it does not typically cause glucose intolerance, hypertension, or renal insufficiency.
- Potential adverse effects include hyperlipidemia and hepatic artery thrombosis in liver transplant recipients.
Conclusions:
- Sirolimus presents significant potential advantages over conventional immunosuppressive agents in liver transplantation.
- Its antifibrotic and antineoplastic effects warrant further investigation for patient benefit.
- Careful consideration of its distinct side-effect profile is crucial for optimal patient management.
